Citation Impact
Citing Papers
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
2007 StandoutNobel
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody
2010
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
In Situ B Cell-Mediated Immune Responses and Tubulointerstitial Inflammation in Human Lupus Nephritis
2010
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
2017 Standout
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Immunotherapy of cancer in 2012
2012
The DNA-damage response in human biology and disease
2009 StandoutNature
Control of cancer-related anemia with erythropoietic agents:a review of evidence for improved quality of life and clinical outcomes
2003
Myeloid Growth Factors
2011
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
2008 StandoutNature
Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial
2009
Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
2013
Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma
1999
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
The Treatment of Multiple Myeloma
1994
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
WNT signalling pathways as therapeutic targets in cancer
2012 Standout
Cytokines as a link between innate and adaptive antitumor immunity
2002
Lung Cancer
2008 Standout
Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY
2006
Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation
2011
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
2013
Insight into the Role of Wnt5a-Induced Signaling in Normal and Cancer Cells
2014
Idiopathic Pulmonary Alveolar Proteinosis as an Autoimmune Disease with Neutralizing Antibody against Granulocyte/Macrophage Colony-Stimulating Factor
1999
Immune-mediated side-effects of cytokines in humans
1995
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future
2007
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
2005
Updated Guidelines on the Management of Cytomegalovirus Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Alemtuzumab
2006
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Follicular B helper T cells in antibody responses and autoimmunity
2005
Myasthenia Gravis
1994 Standout
Engineered T cells: the promise and challenges of cancer immunotherapy
2016
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
2006
Induction of neutralising antibodies restricts the use of human granulocyte/macrophage colony stimulating factor for vaccine studies in rhesus macaques
2004 StandoutNobel
Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals
2007
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
2004
Graves' Ophthalmopathy
2010 Standout
Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF)
2004
RNA as a tumor vaccine: a review of the literature
2001
The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
2004
Systemic Lupus Erythematosus
2011 Standout
Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort
2014
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
2010 Standout
Monoclonal antibodies as therapeutic agents for cancer
2004
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Lineage-Specific Hematopoietic Growth Factors
2006
Classification of anticancer drugs—a new system based on therapeutic targets
2003
Emerging causes of iron deficiency anemia refractory to oral iron supplementation
2013
Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer
2009
Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies
1995
Prevalence and outcomes of anemia in cancer: a systematic review of the literature
2004
Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy
1996
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
2009
Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab
2012
Therapeutic vaccines for cancer: an overview of clinical trials
2014
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
Abnormal T‐Cell Expansion and V‐Gene Usage in Myasthenia Gravis Patients
1991
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
2010 Standout
Extracellular mRNA Induces Dendritic Cell Activation by Stimulating Tumor Necrosis Factor-α Secretion and Signaling through a Nucleotide Receptor
2002 StandoutNobel
Ror‐family receptor tyrosine kinases in noncanonical Wnt signaling: Their implications in developmental morphogenesis and human diseases
2009
Kaposi's Sarcoma
2000 Standout
Monoclonal antibodies for cancer immunotherapy
2009
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
1994
DNA and RNA-based vaccines: principles, progress and prospects
1999
Incidence of GM-CSF Antibodies in Cancer Patients Receiving GM-CSF for Immunostimulation
2001
Anemia of Chronic Disease
2005 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models
2001
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements
2007 StandoutNobel
Spontaneously occurring neutralizing antibodies against granulocyte–macrophage colony‐stimulating factor in patients with autoimmune disease
1999
Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology
2002
Stable silencing of ROR1 regulates cell cycle, apoptosis, and autophagy in a lung adenocarcinoma cell line.
2020
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States
2017
Clonal B cells in patients with hepatitis C virus–associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset
2011 StandoutNobel
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
2005 Standout
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation
2003
Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma
1999
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns
2012
Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy
1996
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Cytokine Storm
2020 Standout
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma
1997
Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
1999
Iron Supplementation in Nephrology and Oncology: What Do We Have in Common?
2011
Cancer Genome Landscapes
2013 StandoutScience
Alemtuzumab for patients with chronic lymphocytic leukaemia
2012
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Iron-Deficiency Anemia
2015 Standout
Surface Plasmon Resonance Sensors for Detection of Chemical and Biological Species
2008 Standout
Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases
2009
Regulatory roles of IL-10–producing human follicular T cells
2019 StandoutNobel
BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations.
2003
Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide
2008
Multiple Myeloma
2011 Standout
Quality of life in chronic lymphocytic leukemia: A neglected issue
2005
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
2007
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
2007
Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies
2016
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia
2005
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Antibody to Granulocyte-Macrophage Colony-Stimulating Factor Is a Dominant Anti-Cytokine Activity in Human IgG Preparations
1998
Atomically Precise Clusters of Noble Metals: Emerging Link between Atoms and Nanoparticles
2017 Standout
Works of Anders Österborg being referenced
Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis
2006
Idiotype Immunity (Natural and Vaccine-induced) in Early Stage Multiple Myeloma
2000
Predominant T cell receptor V gene usage in patients with abnormal clones of B cells
1991
Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man
1999
Phase II study of cyclophosphamide, interferon-α and betamethasone (CIB) as induction therapy for patients 60–75 years of age with multiple myeloma stages II and III
2003
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
2004
Natural killer cell activity in monoclonal gammopathies: Relation to disease activity
1990
NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy
2007
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
2008
Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron
2012
Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations
2002
Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors
2006
The biology and treatment of chronic lymphocytic leukemia
2006
A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
2018
Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl‐2 oncoprotein
1995
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
2006
Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells
2010
Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors
1999
Induction of anti-recombinant human granulocyte-macrophage colony- stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients
1994
Blood Dendritic Cells From Myeloma Patients Are Not Infected With Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8)
1998
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
2004
Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden
1993
Randomized Phase II Study of BLP25 Liposome Vaccine (L-BLP25) in Patients with Multiple Myeloma
2011
Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies
2002
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
2003
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
2011
Idiotype Immunization Combined With Granulocyte-Macrophage Colony-Stimulating Factor in Myeloma Patients Induced Type I, Major Histocompatibility Complex–Restricted, CD8- and CD4-Specific T-Cell Responses
1998
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
2002
Idiotype Immunization Combined With Granulocyte-Macrophage Colony-Stimulating Factor in Myeloma Patients Induced Type I, Major Histocompatibility Complex–Restricted, CD8- and CD4-Specific T-Cell Responses
1998
Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone
2004
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
2004
Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma
2005
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
2010
Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma
1996
Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis
2004